[Targeted therapies in breast cancer]

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Improved understanding of breast cancer biology has identified novel therapeutic targets.
• Trastuzumab (anti-HER2 monoclonal antibody) and lapatinib (tyrosine kinase inhibitor) are established treatments for HER2-overexpressing breast cancer.
• The landscape of breast cancer treatment is continually evolving with new targeted therapies.

Purpose of the Study:

• To review current and emerging targeted therapies for HER2-overexpressing breast cancer.
• To discuss novel anti-HER2 agents and drugs targeting downstream signaling pathways.
• To highlight other targeted treatments relevant to breast cancer, including antiangiogenic and PI3K-AKT-mTOR pathway inhibitors.

Main Methods:

• Literature review of targeted therapies in breast cancer.
• Analysis of clinical data for HER2-targeted agents.
• Discussion of emerging treatment strategies and pathways.

Main Results:

• Trastuzumab and lapatinib are key treatments for HER2-positive breast cancer.
• New agents like pertuzumab and T-DM1, along with pathway inhibitors, are under evaluation.
• Antiangiogenic agents and PI3K-AKT-mTOR pathway drugs represent other promising avenues.

Conclusions:

• Targeted therapies have significantly advanced breast cancer treatment, particularly for HER2-overexpressing subtypes.
• Combination strategies and novel agents offer future treatment options.
• Continued research into molecular pathways is crucial for developing more effective breast cancer therapies.